Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 121
- Registration Number
- NCT00000940
- Locations
- 🇺🇸
SSTAR, Family Healthcare Ctr., Fall River, Massachusetts, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
🇺🇸USC CRS, Los Angeles, California, United States
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
- Conditions
- AIDS Dementia ComplexHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002163
- Locations
- 🇺🇸
Johns Hopkins Univ School of Medicine, Baltimore, Maryland, United States
🇺🇸Mount Sinai Med Ctr, New York, New York, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
- Conditions
- HIV InfectionsLipodystrophy
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 100
- Registration Number
- NCT00005764
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
🇺🇸St Lukes Medical Group, San Diego, California, United States
A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 80
- Registration Number
- NCT00002440
- Locations
- 🇺🇸
Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit, New Haven, Connecticut, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
🇺🇸UCSD Treatment Ctr, San Diego, California, United States
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002217
- Locations
- 🇺🇸
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002419
- Locations
- 🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pacific Oaks Med Group, Beverly Hills, California, United States
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 550
- Registration Number
- NCT00002199
- Locations
- 🇺🇸
Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Burroughs Wellcome
- Target Recruit Count
- 18
- Registration Number
- NCT00002141
- Locations
- 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Ctr for Phase I Research, Wichita, Kansas, United States
Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 230
- Registration Number
- NCT00004981
- Locations
- 🇺🇸
Tower Infectious Disease Med Ctr, Los Angeles, California, United States
🇺🇸St Lukes Medical Group, San Diego, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 400
- Registration Number
- NCT00011895
- Locations
- 🇺🇸
Therapeutic Concepts, Houston, Texas, United States
🇺🇸Diversified Med Practices, PA, Houston, Texas, United States
🇺🇸Infectious Diseases Associates of Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.